+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
GalNAc-siRNA Conjugates Drug Market - Global Forecast 2026-2032- Product Image
GalNAc-siRNA Conjugates Drug Market - Global Forecast 2026-2032- Product Image
Sale

GalNAc-siRNA Conjugates Drug Market - Global Forecast 2026-2032

  • Report

  • 188 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6121562
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The GalNAc-siRNA Conjugates Drug Market is projected to reach USD 1.19 Billion in 2026. It is expected to continue growing at a CAGR of 7.45%, reaching USD 1.82 Billion by 2032.

GalNAc-siRNA Conjugates: A Targeted Approach to RNA Interference Therapy

GalNAc-siRNA conjugates are medicines designed to deliver small interfering RNA (siRNA) selectively to hepatocytes through the asialoglycoprotein receptor. This mechanism can enable durable gene silencing after subcutaneous administration and is particularly relevant to liver-mediated diseases. The therapeutic approach has progressed from experimental RNA interference into regulated clinical use, while ongoing research is addressing delivery, durability, safety, and the expansion of treatable targets.

Clinical Validation Is Shifting RNAi From Novelty to Therapeutic Platform

The landscape is being reshaped by improved conjugate chemistry, more predictable hepatocyte uptake, and clinical evidence supporting infrequent dosing. Development is increasingly focused on genetically defined diseases, chronic conditions, and targets where sustained suppression may offer advantages over daily small-molecule or protein therapies. Important considerations include on-target and off-target effects, immunogenicity, liver monitoring, treatment adherence, payer evidence, and the practical integration of genetic testing into diagnosis.

Artificial Intelligence Accelerates Target Selection, Design, and Evidence Generation

Artificial intelligence can support GalNAc-siRNA development by analyzing genomic and transcriptomic data, prioritizing disease-driving targets, designing siRNA sequences, and identifying potential off-target interactions. It can also assist biomarker discovery, patient stratification, pharmacovigilance, and the interpretation of longitudinal clinical data. Human review remains essential because computational predictions require laboratory and clinical validation, particularly for tissue specificity, immune responses, dose selection, and clinically meaningful outcomes.

Regional Dynamics Reflect Differences in Regulation, Infrastructure, and Rare-Disease Access

North America benefits from established RNA therapeutics expertise, specialized clinical networks, and comparatively mature regulatory pathways. Europe combines strong translational research with complex national reimbursement and health-technology-assessment requirements. Asia-Pacific is advancing through growing biopharmaceutical capabilities, expanding genomic infrastructure, and rising interest in precision medicine. Latin America presents opportunities linked to specialist care and diagnostic development, while access can be affected by funding and distribution constraints. The Middle East is building precision-health capacity, particularly through national health programs, and Africa requires greater investment in genetic diagnosis, specialist services, and equitable delivery systems.

Economic and Security Alliances Shape Collaboration and Access Priorities

ASEAN countries are developing uneven but increasingly connected biomedical and regulatory capabilities, creating opportunities for regional trial coordination and diagnostic partnerships. BRICS members span major research, manufacturing, and healthcare systems, but differ substantially in regulatory maturity and access conditions. The European Union emphasizes coordinated scientific standards alongside country-level reimbursement decisions. G7 members contribute substantial research, regulatory, and clinical expertise. GCC states are investing in advanced healthcare infrastructure and genomics, while NATO countries may support broader resilience in biomedical supply chains, research collaboration, and health-security preparedness.

Country-Level Readiness Depends on Science, Regulation, Diagnosis, and Reimbursement

The United States and Canada have strong clinical-research ecosystems and experience with advanced therapeutics. The United Kingdom, France, Germany, Italy, and Spain combine specialist academic capacity with distinct national access and assessment processes. Japan and South Korea have sophisticated pharmaceutical and diagnostic infrastructures, while China is expanding RNA research, clinical capabilities, and domestic biomanufacturing. India is strengthening biotechnology and precision-medicine capacity, though access varies across regions. Australia supports high-quality clinical research and regulated medicine access. Brazil and Mexico have important specialist centers but face uneven distribution of advanced diagnostics and treatment. Russia retains scientific and clinical capabilities, while regulatory, supply, and international collaboration conditions influence development and access.

Leaders Should Pair Molecular Innovation With Evidence, Access, and Delivery Readiness

Industry leaders should prioritize targets with strong human genetic validation and clinically measurable outcomes, then use sequence-screening and experimental confirmation to manage off-target risk. Development plans should incorporate durable-response assessment, liver safety monitoring, patient-reported outcomes, and comparative evidence relevant to reimbursement decisions. Partnerships with diagnostic providers can improve identification of genetically appropriate patients, while manufacturing plans should protect oligonucleotide, conjugation, and sterile-fill supply continuity. Regional launch strategies should reflect local regulatory pathways, specialist capacity, genetic-testing availability, and affordability mechanisms rather than relying on a uniform global model.

Methodology: Evidence-Based Review of Biology, Development, Regulation, and Access

This executive summary uses a structured review of publicly documented scientific literature, clinical-trial records, regulatory materials, treatment guidelines, health-system publications, and relevant biotechnology research. Findings were organized around mechanism of action, clinical translation, artificial-intelligence applications, regional conditions, institutional groupings, country readiness, and implementation priorities. Claims were limited to established or clearly documented developments; no market estimates, market sizing, market shares, or forecasts were used.

GalNAc-siRNA Conjugates Are Advancing Through Precision, Durability, and Delivery Discipline

GalNAc-siRNA conjugates have established a credible route for selective hepatic gene silencing and are broadening the therapeutic possibilities of RNA interference. Future progress will depend not only on better sequences and conjugate designs, but also on reliable diagnosis, long-term safety evidence, sustainable manufacturing, appropriate reimbursement, and equitable specialist access. Organizations that connect molecular innovation with real-world care infrastructure will be best positioned to translate the platform’s biological advantages into durable patient benefit.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. GalNAc-siRNA Conjugates Drug Market, by Indication
7.1. Introduction
7.2. Metabolic Disorders
7.2.1. Hypercholesterolemia
7.2.2. Type 2 Diabetes
7.3. Oncology
7.4. Rare Diseases
7.4.1. Hattr Amyloidosis
7.4.2. Hemophilia A
8. GalNAc-siRNA Conjugates Drug Market, by Patient Age Group
8.1. Introduction
8.2. Adults
8.3. Pediatric
9. GalNAc-siRNA Conjugates Drug Market, by Application Type
9.1. Introduction
9.2. Prophylaxis
9.3. Treatment
10. GalNAc-siRNA Conjugates Drug Market, by End User
10.1. Introduction
10.2. Home Healthcare
10.3. Hospitals
10.4. Research Institutes
10.5. Specialty Clinics
11. GalNAc-siRNA Conjugates Drug Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. GalNAc-siRNA Conjugates Drug Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. GalNAc-siRNA Conjugates Drug Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. GalNAc-siRNA Conjugates Drug Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Akcea Therapeutics, Inc.
16.2. Alnylam Pharmaceuticals, Inc.
16.3. Arrowhead Pharmaceuticals, Inc.
16.4. AstraZeneca plc
16.5. BioNTech SE
16.6. CureVac N.V.
16.7. Dicerna Pharmaceuticals, Inc.
16.8. GlaxoSmithKline plc
16.9. Ionis Pharmaceuticals, Inc.
16.10. Moderna, Inc.
16.11. Novartis AG
16.12. Novo Nordisk A/S
16.13. Pfizer Inc.
16.14. Roche Holding AG
16.15. Sanofi S.A.
16.16. Sarepta Therapeutics, Inc.
16.17. Takeda Pharmaceutical Company Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global GalNAc-siRNA Conjugates Drug Market, Years Considered for the Study
FIGURE 2. Global GalNAc-siRNA Conjugates Drug Market, Research Design
FIGURE 3. Global GalNAc-siRNA Conjugates Drug Market, Research Framework
FIGURE 4. Global GalNAc-siRNA Conjugates Drug Market, Data Triangulation
FIGURE 5. Global GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
FIGURE 6. Global GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2025 vs 2032 (%)
FIGURE 9. Global GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2025 vs 2032 (%)
FIGURE 11. Global GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global GalNAc-siRNA Conjugates Drug Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global GalNAc-siRNA Conjugates Drug Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 15. Global GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global GalNAc-siRNA Conjugates Drug Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global GalNAc-siRNA Conjugates Drug Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global GalNAc-siRNA Conjugates Drug Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global GalNAc-siRNA Conjugates Drug Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global GalNAc-siRNA Conjugates Drug Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global GalNAc-siRNA Conjugates Drug Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global GalNAc-siRNA Conjugates Drug Market Segmentation & Coverage
TABLE 2. Global GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 3. Global GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Metabolic Disorders Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Metabolic Disorders Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Metabolic Disorders Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Hypercholesterolemia Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Hypercholesterolemia Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Hypercholesterolemia Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Type 2 Diabetes Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Type 2 Diabetes Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Type 2 Diabetes Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Rare Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Rare Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Rare Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Hattr Amyloidosis Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Hattr Amyloidosis Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Hattr Amyloidosis Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Hemophilia A Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Hemophilia A Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Hemophilia A Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 26. Global Adults Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Adults Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Adults Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 33. Global Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 40. Global Home Healthcare Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Home Healthcare Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Home Healthcare Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 53. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global GalNAc-siRNA Conjugates Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific GalNAc-siRNA Conjugates Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 71. North America GalNAc-siRNA Conjugates Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. North America GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 73. North America GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 74. North America GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 75. North America GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 76. North America GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 77. North America GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 78. North America GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 79. Latin America GalNAc-siRNA Conjugates Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Latin America GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 81. Latin America GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 82. Latin America GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 83. Latin America GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 84. Latin America GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 85. Latin America GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 86. Latin America GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 87. Europe GalNAc-siRNA Conjugates Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Europe GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 89. Europe GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 90. Europe GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 91. Europe GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 92. Europe GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 93. Europe GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. Europe GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 95. Middle East GalNAc-siRNA Conjugates Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Middle East GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 97. Middle East GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 98. Middle East GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 99. Middle East GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 100. Middle East GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 101. Middle East GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 102. Middle East GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 103. Africa GalNAc-siRNA Conjugates Drug Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Africa GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 105. Africa GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 106. Africa GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 107. Africa GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 108. Africa GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 109. Africa GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. Africa GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 111. Global GalNAc-siRNA Conjugates Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. ASEAN GalNAc-siRNA Conjugates Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. ASEAN GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 114. ASEAN GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 115. ASEAN GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 116. ASEAN GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 117. ASEAN GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 118. ASEAN GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 119. ASEAN GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 120. GCC GalNAc-siRNA Conjugates Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. GCC GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 122. GCC GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 123. GCC GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 124. GCC GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 125. GCC GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 126. GCC GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 127. GCC GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 128. European Union GalNAc-siRNA Conjugates Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 129. European Union GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 130. European Union GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 131. European Union GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 132. European Union GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 133. European Union GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 134. European Union GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. European Union GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 136. BRICS GalNAc-siRNA Conjugates Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 137. BRICS GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 138. BRICS GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 139. BRICS GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 140. BRICS GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 141. BRICS GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 142. BRICS GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. BRICS GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 144. G7 GalNAc-siRNA Conjugates Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. G7 GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 146. G7 GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 147. G7 GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 148. G7 GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 149. G7 GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 150. G7 GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. G7 GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 152. NATO GalNAc-siRNA Conjugates Drug Market Size, by Group, 2017-2032 (USD Million)
TABLE 153. NATO GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 154. NATO GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 155. NATO GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 156. NATO GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 157. NATO GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 158. NATO GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. NATO GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 160. Global GalNAc-siRNA Conjugates Drug Market Size, by Country, 2017-2032 (USD Million)
TABLE 161. United States GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 162. United States GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 163. United States GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 164. United States GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 165. United States GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 166. United States GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 167. United States GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 168. United States GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 169. Canada GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 170. Canada GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 171. Canada GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 172. Canada GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 173. Canada GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 174. Canada GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 175. Canada GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 176. Canada GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. Mexico GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 178. Mexico GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 179. Mexico GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 180. Mexico GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 181. Mexico GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 182. Mexico GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 183. Mexico GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 184. Mexico GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 185. Brazil GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 186. Brazil GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 187. Brazil GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 188. Brazil GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 189. Brazil GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 190. Brazil GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 191. Brazil GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 192. Brazil GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 193. United Kingdom GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 194. United Kingdom GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 195. United Kingdom GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 196. United Kingdom GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 197. United Kingdom GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 198. United Kingdom GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 199. United Kingdom GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 200. United Kingdom GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 201. Germany GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 202. Germany GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 203. Germany GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 204. Germany GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 205. Germany GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 206. Germany GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 207. Germany GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. Germany GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 209. France GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 210. France GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 211. France GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 212. France GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 213. France GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 214. France GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 215. France GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. France GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 217. Russia GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 218. Russia GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 219. Russia GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 220. Russia GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 221. Russia GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 222. Russia GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 223. Russia GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 224. Russia GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 225. Italy GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 226. Italy GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 227. Italy GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 228. Italy GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 229. Italy GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 230. Italy GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 231. Italy GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 232. Italy GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 233. Spain GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 234. Spain GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 235. Spain GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 236. Spain GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 237. Spain GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 238. Spain GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 239. Spain GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 240. Spain GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 241. China GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 242. China GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 243. China GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 244. China GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 245. China GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 246. China GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 247. China GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. China GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 249. India GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 250. India GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 251. India GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 252. India GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 253. India GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 254. India GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 255. India GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 256. India GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 257. Japan GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 258. Japan GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 259. Japan GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 260. Japan GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 261. Japan GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 262. Japan GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 263. Japan GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 264. Japan GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 265. Australia GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 266. Australia GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 267. Australia GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 268. Australia GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 269. Australia GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 270. Australia GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 271. Australia GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 272. Australia GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 273. South Korea GalNAc-siRNA Conjugates Drug Market Size, 2017-2032 (USD Million)
TABLE 274. South Korea GalNAc-siRNA Conjugates Drug Market Size, by Indication, 2017-2032 (USD Million)
TABLE 275. South Korea GalNAc-siRNA Conjugates Drug Market Size, by Metabolic Disorders, 2017-2032 (USD Million)
TABLE 276. South Korea GalNAc-siRNA Conjugates Drug Market Size, by Rare Diseases, 2017-2032 (USD Million)
TABLE 277. South Korea GalNAc-siRNA Conjugates Drug Market Size, by Patient Age Group, 2017-2032 (USD Million)
TABLE 278. South Korea GalNAc-siRNA Conjugates Drug Market Size, by Application Type, 2017-2032 (USD Million)
TABLE 279. South Korea GalNAc-siRNA Conjugates Drug Market Size, by End User, 2017-2032 (USD Million)
TABLE 280. South Korea GalNAc-siRNA Conjugates Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 281. Global GalNAc-siRNA Conjugates Drug Market Share, by Key Player, 2025
TABLE 282. Global GalNAc-siRNA Conjugates Drug Market, Key Experts

Companies Mentioned

  • Akcea Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • BioNTech SE
  • CureVac N.V.
  • Dicerna Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Ionis Pharmaceuticals, Inc.
  • Moderna, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Sarepta Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

RNA Therapies - Competitive Landscape, 2026 - Product Image

RNA Therapies - Competitive Landscape, 2026

  • Report
  • 280 Pages
  • Global
From
GalNAc-based Drug Market - Global Forecast 2026-2032 - Product Image

GalNAc-based Drug Market - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
RNA Therapy Market - Global Forecast 2026-2032 - Product Image

RNA Therapy Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Amvuttra Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Amvuttra Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 250 Pages
  • Global
From
Leqvio Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Leqvio Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.